6MO9

N-terminal bromodomain of human BRD2 in complex with N-cyclopentyl-7-(3,5-dimethylisoxazol-4-yl)quinoline-5-sulfonamide inhibitor

Summary for 6MO9

• Entry DOI: 10.2210/pdb6mo9/pdb
• Descriptor: Bromodomain-containing protein 2, N-cyclopentyl-7-(3,5-dimethyl-1,2-oxazol-4-yl)quinoline-5-sulfonamide (3 entities in total)
• Functional Keywords: inhibitor, epigenetic reader, bromo domain, transcription-transcription inhibitor complex, transcription/transcription inhibitor
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 3
• Total formula weight: 45863.67

Authors

Lansdon, E.B.,Newby, Z.E.R. (deposition date: 2018-10-04, release date: 2019-01-23, Last modification date: 2024-03-13)

• Primary citation: Sperandio, D.,Aktoudianakis, V.,Babaoglu, K.,Chen, X.,Elbel, K.,Chin, G.,Corkey, B.,Du, J.,Jiang, B.,Kobayashi, T.,Mackman, R.,Martinez, R.,Yang, H.,Zablocki, J.,Kusam, S.,Jordan, K.,Webb, H.,Bates, J.G.,Lad, L.,Mish, M.,Niedziela-Majka, A.,Metobo, S.,Sapre, A.,Hung, M.,Jin, D.,Fung, W.,Kan, E.,Eisenberg, G.,Larson, N.,Newby, Z.E.R.,Lansdon, E.,Tay, C.,Neve, R.M.,Shevick, S.L.,Breckenridge, D.G.; Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.; Bioorg. Med. Chem., 27:457-469, 2019; PubMed: 30606676; DOI: 10.1016/j.bmc.2018.11.020

Experimental method

X-RAY DIFFRACTION (1.801 Å)